Estimation of plasma apolipoprotein B concentration using routinely measured lipid biochemical tests in apparently healthy Asian adults

Cardiovascular Diabetology

Volumn 11, Issue , 2012, Pages

  Cho, Dong Sik ^a   Woo, Sookyoung ^b   Kim, Seonwoo ^b   Byrne, Christopher D ^c   Kong, Joon Hyuk ^a   Sung, Ki Chul ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Samsung Medical Center   (South Korea)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Apolipoprotein; Cholesterol; Formula; Hypercholesterolemia; Lipid

Indexed keywords

APOLIPOPROTEIN B; LIPID; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; ASIAN; BIOCHEMISTRY; CARDIOVASCULAR RISK; CLINICAL PRACTICE; FEMALE; HUMAN; KOREA; LIPID ANALYSIS; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ALGORITHMS; APOLIPOPROTEIN B-100; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MARKERS; BLOOD CHEMICAL ANALYSIS; BODY MASS INDEX; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FEMALE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; REPUBLIC OF KOREA; TRIGLYCERIDES;

EID: 84861116249     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-11-55     Document Type: Article

References (34)

1. Bairaktari E, Hatzidimou K, Tzallas C, Vini M, Katsaraki A, Tselepis A, Elisaf M, Tsolas O. Estimation of LDL cholesterol based on the Friedewald formula and on apo B levels. Clin Biochem 2000, 33:549-555. 10.1016/S0009-9120(00)00162-4, 11124340.
2. Kannel WB, Castelli WP, Gordon T. Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham study. Ann Intern Med 1979, 90:85-91.
3. Gordon T, Kannel WB, Castelli WP, Dawber TR. Lipoproteins cardiovascular disease and death. The Framingham study. Archives Internal Med 1981, 141:1128-1131.
4. Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Munster study. The Am J Cardiology 1992, 70:733-737.
5. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA : J Am Med Assoc 1993, 269:3015-3023. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults.
6. Ko M, Kim MT, Nam JJ. Assessing risk factors of coronary heart disease and its risk prediction among Korean adults: the 2001 Korea National Health and Nutrition Examination Survey. Int J Cardiol 2006, 110:184-190. 10.1016/j.ijcard.2005.07.030, 16412525.
7. Hobbs FD. Reducing cardiovascular risk in diabetes: beyond glycemic and blood pressure control. Int J Cardiol 2006, 110:137-145. 10.1016/j.ijcard.2005.09.011, 16289373.
8. Keech A, Colquhoun D, Best J, Kirby A, Simes RJ, Hunt D, Hague W, Beller E, Arulchelvam M, Baker J, et al. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care 2003, 26:2713-2721. 10.2337/diacare.26.10.2713, 14514569.
9. Bairaktari E, Elisaf M, Tzallas C, Karabina SA, Tselepis AD, Siamopoulos KC, Tsolas O. Evaluation of five methods for determining low-density lipoprotein cholesterol (LDL-C) in hemodialysis patients(1). Clin Biochem 2001, 34:593-602. 10.1016/S0009-9120(01)00274-0, 11849617.
10. Raza JA, Babb JD, Movahed A. Optimal management of hyperlipidemia in primary prevention of cardiovascular disease. Int J Cardiol 2004, 97:355-366. 10.1016/j.ijcard.2003.07.039, 15561319.
11. International Taskforce for Prevention of Coronary Heart Disease Prevention of coronary heart disease: scientific background and clinical guidelines. Nutr Metab Cardiovasc Dis 1992, 2:113-156. International Taskforce for Prevention of Coronary Heart Disease.
12. Haffner SM. Dyslipidemia management in adults with diabetes. Diabetes Care 2004, 27(Suppl 1):S68-S71.
13. Cho YK, Hur SH, Han CD, Park HS, Yoon HJ, Kim H, Nam CW, Kim YN, Kim KB, Park NH, Park HJ. Comparison of Ezetimibe/Simvastatin 10/20 mg Versus Atorvastatin 20 mg in Achieving a Target Low Density Lipoprotein-Cholesterol Goal for Patients With Very High Risk. Korean Circ J 2011, 41(3):149-153. 10.4070/kcj.2011.41.3.149, 3079135, 21519514.
14. Choi SJ, Park SH, Lee KS, HY P. The prevalence, awareness and treatment of high low density lipoprotein-cholesterol in korean adults without coronary heart diseases - the third Korea national health and nutrition examination survey, 2005 .-Korean. Circ J 2012, 42(2):86-94.
15. Davidson MH. Apolipoprotein measurements: is more widespread use clinically indicated?. Clin Cardiol 2009, 32:482-486. 10.1002/clc.20559, 19743499.
16. National Cholesterol Education Program (NCEP) Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143-3421. National Cholesterol Education Program (NCEP) Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).
17. Rizzo M, Berneis K. Should we measure routinely the LDL peak particle size?. Int J Cardiol 2006, 107:166-170. 10.1016/j.ijcard.2005.02.035, 16412793.
18. Rosenson RS, Otvos JD, Hsia J. Effects of rosuvastatin and atorvastatin on LDL and HDL particle concentrations in patients with metabolic syndrome: a randomized, double-blind, controlled study. Diabetes Care 2009, 32:1087-1091. 10.2337/dc08-1681, 2681027, 19265025.
19. Li, et al. Serum Non-high-density lipoprotein cholesterol concentration and risk of death from cardiovascular diseases among U.S. adults with diagnosed diabetes: the Third National Health and Nutrition Examination Survey linked mortality study. Cardiovasc Diabetol 2011, 10:46. 10.1186/1475-2840-10-46, 3127754, 21605423.
20. Hermans, et al. log(TG)/HDL-C is related to both residual cardiometabolic risk and b-cell function loss in type 2 diabetes males. Cardiovasc Diabetol 2010, 9:88. 10.1186/1475-2840-9-88, 3020173, 21156040.
21. Marcovina S, Packard CJ. Measurement and meaning of apolipoprotein AI and apolipoprotein B plasma levels. J Internal Med 2006, 259:437-446. 10.1111/j.1365-2796.2006.01648.x, 16629849.
22. Walldius G, Jungner I. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy-a review of the evidence. J Internal Med 2006, 259:493-519. 10.1111/j.1365-2796.2006.01643.x, 16629855.
23. Hermans MP, Sacks FM, Ahn SA, Rousseau MF. Non-HDL-cholesterol as valid surrogate to apolipoprotein B100 measurement in diabetes: Discriminant Ratio and unbiased equivalence. Cardiovasc Diabetol 2011, 10:20. 10.1186/1475-2840-10-20, 3056766, 21356116.
24. Jiang R, Schulze MB, Li T, Rifai N, Stampfer MJ, Rimm EB, Hu FB. Non-HDL cholesterol and apolipoprotein B predict cardiovascular disease events among men with type 2 diabetes. Diabetes Care 2004, 27:1991-1997. 10.2337/diacare.27.8.1991, 15277429.
25. Contois JH, McConnell JP, Sethi AA, Csako G, Devaraj S, Hoefner DM, Warnick GR. Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices. Clin Chem 2009, 55:407-419. 10.1373/clinchem.2008.118356, 19168552.
26. Barter PJ, Ballantyne CM, Carmena R, Castro Cabezas M, Chapman MJ, Couture P, de Graaf J, Durrington PN, Faergeman O, Frohlich J, et al. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J Internal Med 2006, 259:247-258. 10.1111/j.1365-2796.2006.01616.x, 16476102.
27. Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howard BV, Stein JH, Witztum JL. Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol 2008, 51:1512-1524. 10.1016/j.jacc.2008.02.034, 18402913.
28. Kim BJ, Hwang ST, Sung KC, Kim BS, Kang JH, Lee MH, Park JR. Comparison of the relationships between serum apolipoprotein B and serum lipid distributions. Clin Chem 2005, 51:2257-2263. 10.1373/clinchem.2005.052738, 16214827.
29. Charlton-Menys V, Betteridge DJ, Colhoun H, Fuller J, France M, Hitman GA, Livingstone SJ, Neil HA, Newman CB, Szarek M, et al. Targets of statin therapy: LDL cholesterol, non-HDL cholesterol, and apolipoprotein B in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS). Clin Chem 2009, 55:473-480. 10.1373/clinchem.2008.111401, 19147732.
30. Kim HK, Chang SA, Choi EK, Kim YJ, Kim HS, Sohn DW, Oh BH, Lee MM, Park YB, Choi YS. Association between plasma lipids, and apolipoproteins and coronary artery disease: a cross-sectional study in a low-risk Korean population. Int J Cardiol 2005, 101:435-440. 10.1016/j.ijcard.2004.03.057, 15907412.
31. Genest J, Frohlich J, Fodor G, McPherson R. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. CMAJ : Canadian Med Assoc J = Journal de l'Association Medicale canadienne 2003, 169:921-924.
32. Williams K, Sniderman AD, Sattar N, D'Agostino R, Wagenknecht LE, Haffner SM. Comparison of the associations of apolipoprotein B and low-density lipoprotein cholesterol with other cardiovascular risk factors in the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2003, 108:2312-2316. 10.1161/01.CIR.0000097113.11419.9E, 14581403.
33. Kulkarni K. Apo B measurement system and method. 2008. Agents: DLA PIPER US LLP; IPC8 Class: AG01N3392FI; USPC Class: 436 52 http://www.faqs.org/patents/app/20080261313.
34. Chen Z, Strack AM, Stefanni AC, Chen Y, Wu W, Pan Y, Urosevic-Price O, Wang L, McLaughlin T, Geoghagen N, Lassman ME, Roddy TP, Wong KK, Hubbard BK, Flattery AM. Validation of human ApoB and ApoAI immunoturbidity assays for non-human primate dyslipidemia and atherosclerosis research. J Cardiovasc Transl Res 2011, 4:373-383. 10.1007/s12265-011-9264-4, 21394531.